Therefore, the block of both MEK and PI3K/AKT/mTOR pathways with a combination of different signalling inhibitors may be used to more effectively target tumor cells, as compared with treatment with a single agent (Figure 1). The gene discussed is AKT1; the disease is neoplasm.